Genomic monitoring of SARS-CoV-2 variants using sentinel SARI hospital surveillance.
SARI surveillance
SARS‐CoV‐2
genomic surveillance
influenza
pandemic preparedness
respiratory viruses
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
08
07
2023
revised:
04
09
2023
accepted:
05
09
2023
medline:
23
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
To support the COVID-19 pandemic response, many countries, including Belgium, implemented baseline genomic surveillance (BGS) programs aiming to early detect and characterize new SARS-CoV-2 variants. In parallel, Belgium maintained a sentinel network of six hospitals that samples patients with severe acute respiratory infections (SARI) and integrated SARS-CoV-2 detection within a broader range of respiratory pathogens. We evaluate the ability of the SARI surveillance to monitor general trends and early signals of viral genetic evolution of SARS-CoV-2 and compare it with the BGS as a reference model. Nine-hundred twenty-five SARS-CoV-2 positive samples from patients fulfilling the Belgian SARI definition between January 2020 and December 2022 were sequenced using the ARTIC Network amplicon tiling approach on a MinION platform. Weekly variant of concern (VOC) proportions and types were compared to those that were circulating between 2021 and 2022, using 96,251 sequences of the BGS. SARI surveillance allowed timely detection of the Omicron (BA.1, BA.2, BA.4, and BA.5) and Delta (B.1.617.2) VOCs, with no to 2 weeks delay according to the start of their epidemic growth in the Belgian population. First detection of VOCs B.1.351 and P.1 took longer, but these remained minor in Belgium. Omicron BA.3 was never detected in SARI surveillance. Timeliness could not be evaluated for B.1.1.7, being already major at the start of the study period. Genomic surveillance of SARS-CoV-2 using SARI sentinel surveillance has proven to accurately reflect VOCs detected in the population and provides a cost-effective solution for long-term genomic monitoring of circulating respiratory viruses.
Sections du résumé
Background
To support the COVID-19 pandemic response, many countries, including Belgium, implemented baseline genomic surveillance (BGS) programs aiming to early detect and characterize new SARS-CoV-2 variants. In parallel, Belgium maintained a sentinel network of six hospitals that samples patients with severe acute respiratory infections (SARI) and integrated SARS-CoV-2 detection within a broader range of respiratory pathogens. We evaluate the ability of the SARI surveillance to monitor general trends and early signals of viral genetic evolution of SARS-CoV-2 and compare it with the BGS as a reference model.
Methods
Nine-hundred twenty-five SARS-CoV-2 positive samples from patients fulfilling the Belgian SARI definition between January 2020 and December 2022 were sequenced using the ARTIC Network amplicon tiling approach on a MinION platform. Weekly variant of concern (VOC) proportions and types were compared to those that were circulating between 2021 and 2022, using 96,251 sequences of the BGS.
Results
SARI surveillance allowed timely detection of the Omicron (BA.1, BA.2, BA.4, and BA.5) and Delta (B.1.617.2) VOCs, with no to 2 weeks delay according to the start of their epidemic growth in the Belgian population. First detection of VOCs B.1.351 and P.1 took longer, but these remained minor in Belgium. Omicron BA.3 was never detected in SARI surveillance. Timeliness could not be evaluated for B.1.1.7, being already major at the start of the study period.
Conclusions
Genomic surveillance of SARS-CoV-2 using SARI sentinel surveillance has proven to accurately reflect VOCs detected in the population and provides a cost-effective solution for long-term genomic monitoring of circulating respiratory viruses.
Identifiants
pubmed: 37840842
doi: 10.1111/irv.13202
pii: IRV13202
pmc: PMC10570899
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13202Informations de copyright
© 2023 Sciensano and The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Microorganisms. 2021 Jul 20;9(7):
pubmed: 34361977
PLoS One. 2022 Jun 3;17(6):e0269138
pubmed: 35657787
Int J Infect Dis. 2022 Oct;123:25-33
pubmed: 35932968
Influenza Other Respir Viruses. 2016 May;10(3):161-9
pubmed: 26590069
Euro Surveill. 2021 Sep;26(38):
pubmed: 34558405
Viruses. 2022 May 31;14(6):
pubmed: 35746671
Clin Pediatr (Phila). 2023 May;62(4):265-268
pubmed: 36189937
Lancet Glob Health. 2023 Jun;11(6):e815-e816
pubmed: 37202013
Nat Commun. 2022 Mar 3;13(1):1152
pubmed: 35241661
Lancet Microbe. 2020 Jul;1(3):e99-e100
pubmed: 32835336
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Vaccines (Basel). 2021 Nov 16;9(11):
pubmed: 34835265
Viruses. 2022 Jun 14;14(6):
pubmed: 35746765
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):236-240
pubmed: 32362647
Mol Biol Evol. 2021 Apr 13;38(4):1608-1613
pubmed: 33316043
Nat Commun. 2022 Nov 16;13(1):7003
pubmed: 36385137
Environ Res. 2022 Jun;209:112911
pubmed: 35149106
Nat Genet. 2022 Apr;54(4):499-507
pubmed: 35347305
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Cell. 2021 Mar 4;184(5):1127-1132
pubmed: 33581746
Biol Methods Protoc. 2020 Jul 18;5(1):bpaa014
pubmed: 33029559
Antiviral Res. 2022 Feb;198:105252
pubmed: 35085683
Euro Surveill. 2020 Oct;25(39):
pubmed: 33006303
Rev Peru Med Exp Salud Publica. 2022 Jan-Mar;39(1):104-110
pubmed: 35766727
Bull Math Biol. 2014 Jan;76(1):245-60
pubmed: 24272389
Viruses. 2022 Oct 20;14(10):
pubmed: 36298856
J R Stat Soc Ser A Stat Soc. 2022 Nov;185(Suppl 1):S112-S130
pubmed: 37063605
Lancet Glob Health. 2023 Jul;11(7):e1075-e1085
pubmed: 37349034
Viruses. 2022 Jun 14;14(6):
pubmed: 35746768
Lancet Microbe. 2021 Mar;2(3):e105-e114
pubmed: 33937883
Can J Infect Dis Med Microbiol. 2023 Feb 16;2023:6590011
pubmed: 36846348
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Public Health Pract (Oxf). 2023 Jun;5:100358
pubmed: 36686982
PLoS One. 2020 Jul 23;15(7):e0236620
pubmed: 32702051
BMC Infect Dis. 2015 Jan 08;15:1
pubmed: 25567701
N Engl J Med. 2018 Jan 4;378(1):7-9
pubmed: 29185857
Science. 2021 Oct 22;374(6566):423-431
pubmed: 34672751
Nat Aging. 2023 Jun;3(6):722-733
pubmed: 37217661
Eur J Epidemiol. 1992 Jul;8(4):485-90
pubmed: 1397213
Nat Rev Microbiol. 2023 Mar;21(3):162-177
pubmed: 36653446
Antiviral Res. 2022 Feb;198:105253
pubmed: 35066015
Front Med (Lausanne). 2022 Feb 22;9:815389
pubmed: 35273977
Life (Basel). 2022 Jan 28;12(2):
pubmed: 35207482
Euro Surveill. 2023 May;28(21):
pubmed: 37227298
BMJ. 2020 Dec 16;371:m4857
pubmed: 33328153